Chemical Component Summary

Name[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
Identifiers2-[1-(aminomethyl)cyclohexyl]ethanoic acid
FormulaC9 H17 N O2
Molecular Weight171.24
TypeNON-POLYMER
Isomeric SMILESNCC1(CC(O)=O)CCCCC1
InChIInChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)
InChIKeyUGJMXCAKCUNAIE-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count29
Chiral Atom Count0
Chiral Atomsn/a
Bond Count29
Aromatic Bond Count0
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00996 Different stereochemistry
NameGabapentin
Groups
  • approved
  • investigational
DescriptionGabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain. Gabapentin is well tolerated in most patients, has a relatively mild side-effect profile, and passes through the body unmetabolized.
Synonyms
  • 1-(Aminomethyl)cyclohexaneacetic acid
  • Gabapentin GR
  • Gabapentina
  • Gabapentine
  • Gabapentino
Brand Names
  • Act Gabapentin
  • Apo-gabapentin
  • Apo-gabapentin Capsules
  • Auro-gabapentin
  • Auro-gabapentin Tablets
Affected OrganismHumans and other mammals
IndicationFor the management of postherpetic neuralgia in adults and as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy.
PharmacologyGabapentin, an analog of GABA, is used as an anticonvulsant to treat partial seizures, amyotrophic lateral sclerosis (ALS), and painful neuropathies. Potential uses include monotherapy of refractory partial seizure disorders, and treatment of spasticity in multiple sclerosis, tremor. mood disorders, and attenuation of disruptive behaviors in dementia. Gabapentin has high lipid solubility, is not metabolized by the liver, has no protein binding, and doesn't possess the usual drug interactions.
Mechanism of actionGabapentin interacts with cortical neurons at auxillary subunits of voltage-sensitive calcium channels. Gabapentin increases the synaptic concentration of GABA, enhances GABA responses at non-synaptic sites in neuronal tissues, and reduces the release of mono-amine neurotransmitters. One of the mechanisms implicated in this effect of gabapentin is the reduction of the axon excitability measured as an amplitude change of the presynaptic fibre volley (FV) in the CA1 area of the hippocampus. This is mediated through its binding to presynaptic NMDA receptors. Other studies have shown that the antihyperalgesic and antiallodynic effects of gabapentin are mediated by the descending noradrenergic system, resulting in the activation of spinal alpha2-adrenergic receptors. Gabapentin has also been shown to bind and activate the adenosine A1 receptor.
Route of administration
  • Oral
  • Topical
Categories
  • Acids, Acyclic
  • Acids, Carbocyclic
  • Amino Acids
  • Amino Acids, Peptides, and Proteins
  • Aminobutyrates
ATC-CodeN03AX12
AHFS-Code28:12.92
CAS number60142-96-3
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682